🇺🇸 FDA
Patent

US 11752137

Ophthalmic compositions for treating ocular Demodex using lotilaner formulations

granted A61KA61K31/42A61K31/422

Quick answer

US patent 11752137 (Ophthalmic compositions for treating ocular Demodex using lotilaner formulations) held by Tarsus Pharmaceuticals, Inc. expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Tarsus Pharmaceuticals, Inc.
Grant date
Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/42, A61K31/422, A61K47/26, A61K9/0048